Beijing News (Reporter Wang Lu) — On December 15, HISUN announced that its wholly-owned subsidiary, Hanzhong Pharmaceutical, had received the "Drug Supplemental Application Approval Notice" issued by the National Medical Products Administration for its product Sodium Succinate Methylprednisolone for Injection. The approval allows Pfizer SA to transfer the production technology of the 40mg and 500mg specifications of the imported drug to Hanzhong Pharmaceutical, and corresponding revisions will be made to the drug approval number, instructions, and packaging labels.
Sodium Succinate Methylprednisolone for Injection, trade name Medrol, is an original researched drug marketed in China. Unless used as replacement therapy for certain endocrine disorders, glucocorticoids are only a symptomatic treatment, including anti-inflammatory treatment, immunosuppressive therapy, treatment of blood diseases and cancer, treatment of shock, endocrine disorders, and others.
The original developer of Sodium Succinate Methylprednisolone for Injection is Pfizer SA. It was one of the varieties injected by Pfizer when Hisun Pharma and Pfizer established a joint venture (now known as Hanzhong Pharma). In January 2022, Hanzhong Pharma submitted a drug production technology transfer application for Sodium Succinate Methylprednisolone for Injection to the National Medical Products Administration, and obtained the approval in December 2023. To date, Hanzhong Pharma has invested approximately 240 million RMB in the Medrol technology transfer project. This drug technology transfer involves the transfer of the original Medrol technology from Pfizer SA to Hanzhong Pharma, which means that Hanzhong Pharma now owns the production rights and ownership of this drug.
According to IQVIA database, the global sales of Sodium Succinate Methylprednisolone for Injection in 2022 were approximately US$387 million, with sales in China reaching about US$126 million; from January to September 2023, the global sales were approximately US$225 million, and sales in China were about US$61.952 million. In 2022, the sales of Jia Qiang Long by Zhejiang Hisun Pharmaceutical Co., Ltd. were approximately RMB 199 million.
On November 28, Hanzhong Pharmaceutical (HISUN) just obtained the production and ownership rights of methylprednisolone tablets (Medrol) from Pfizer Italia s.r.l. Previously, the imported products Meiman, Duoda, and Tazocin, which were injected into Hanzhong Pharmaceutical by Pfizer, have completed localization transfer in China, and Reyataz has achieved sub-packaging.Real Estate。
Proofread by Zhang Yanjun